CTLT 241220 67.50P (CTLT241220P67500) Stock Options, News & Quotes

Account Info

Log Out

US OptionsDetailed Quotes

CTLT241220P67500

Watchlist

0.00
0.000.00%

15min DelayClose Dec 13 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Express News | Novo Nordisk: Not Expecting to Initiate a Share Buyback Programme in 2025
Reuters00:12 ET
Express News | Novo Nordisk: For 2025, Acquisition Is Expected to Have a Mid Single-Digit Negative Impact on Operating Profit Growth
Reuters00:11 ET
Express News | Novo Nordisk: Parties Are Now Free to Close Transaction as Well as Novo Nordisk's Subsequent Acquisition of 3 Catalent Manufacturing Sites From Novo Holdings
Reuters00:11 ET
Express News | Catalent Inc: Transaction Expected to Close in Coming Days
Reuters00:09 ET
Novo Nordisk A/S: The Acquisition of Catalent by Novo Holdings, and the Related Acquisition by Novo Nordisk of Three Manufacturing Sites From Novo Holdings, Is Cleared to Close
GlobeNewswire00:08 ET
Catalent and Novo Holdings Fulfill All Regulatory Closing Conditions for Pending Transaction
Businesswire00:06 ET

Comments

Stella-K

Jun 19 04:18

Which gets me RICH faster: Growth ETF vs. Dividend ETF Investing

I've been on the hunt for a low-risk, yet relatively high-yield investment strategy, and I'm sure many of you feel the same. 🤔While I'm hesitant to dive into stocks like $NVIDIA (NVDA.US)$ , fearing the price might be peaking and a sudden drop is imminent, I also find the stable dividends of companies like $Coca-Cola (KO.US)$ underwhelming for my limited capital. 💡 But recently, I stumbled upon the concept of diversified investing, wh...

Moomoo News Global

Mar 4 08:15

Columns Eli Lilly's Donanemab Nears Approval Decision, Could This Be a Turning Point in Alzheimer's Treatment?

The pharma giant $Eli Lilly and Co (LLY.US)$ is on the cusp of a significant breakthrough with its Alzheimer's drug, donanemab. Following the completion of its Phase 3 trials, donanemab is currently undergoing FDA review and has the potential to receive approval later this month. If approved, it would be the second anti-Aβ therapy for Alzheimer's disease to receive full clearance from the U.S. FD...

100

151364853

Feb 6 12:40

$Catalent (CTLT.US)$ why drop

Bigmoney Dreamer

Feb 5 22:28

$Catalent (CTLT.US)$ 👀63$ all set target

Moomoo Recap US

Feb 5 15:15

Columns Wall Street Today | Stocks Retreat as Fed in No Rush to Cut

RECAP
Stocks Fall as Yields Rise
US stocks fell as yields rose after investors tempered expectations of interest rate cuts this year. Over the weekend, Federal Reserve Chairman Jerome Powell said policymakers are worried that inflation could rear its ugly head and reaccelerate if the central bank moves too soon in lowering borrowing costs.
The $S&P 500 Index (.SPX.US)$ slipped 0.3%, while the tech-heavy $NASDAQ 100 Index (.NDX.US)$ slid 0...

Powell: Not confident rates would lower in March